Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Marstacimab in severe hemophilia
NCT02974855Phase 2Completed
- Sponsor
- Pfizer
- Start
- Mar 2017
- Primary completion
- Dec 2018
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, open-label trial of marstacimab in hemophilia A and hemophilia B (HB) (4 cohorts), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events, Number of Participants Discontinued From Study Due to TEAEs and 13 more. Started Mar 2017; status: completed.
02
Drugs
marstacimab
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT02974855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02974855.